Universe Pharmaceuticals Inc is a company focused on the development, manufacturing, and distribution of high-quality pharmaceutical products, particularly in the realm of traditional Chinese medicine
The company aims to leverage advanced technologies and sustainable practices to create innovative therapeutics that address various health conditions. With a commitment to research and development, Universe Pharmaceuticals also emphasizes the importance of quality control and regulatory compliance in its operations, ensuring that its products meet rigorous industry standards. Through these efforts, the firm seeks to enhance healthcare outcomes and provide accessible solutions for patients globally.
Jiangxi, China, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (Nasdaq: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China today announced that it has entered into a definitive agreement with several investors for the purchase and sale of an aggregate of 18,750,000 of the Company’s ordinary share, par value $0.28125 per share (the “Shares”) (or pre-funded warrants in lieu thereof) at a purchase price of $0.80 per share in a registered direct offering. The purchase price for the pre-funded warrants is identical to the purchase price for Shares, less the exercise price of $0.001 per share.
Jiangxi, China, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQUPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that the Company plans to effect a share consolidation of 15 ordinary shares with par value of US$0.01875 per share each in the Company’s issued and unissued share capital into one (1) ordinary share with par value of US$0.28125 (the “Share Consolidation”). As a result of the Share Consolidation, each 15 pre-consolidation ordinary shares outstanding will automatically combine and convert to one issued and outstanding ordinary share without any action on the part of the shareholders.
Ji’an, Jiangxi, China, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") on October 25, 2024, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq.
